Utama › Kanser Payudara › South Dakota
Kajian klinikal Kanser Payudara di South Dakota
20 kajian untuk Kanser Payudara sedang mencari peserta di lokasi di South Dakota.
Bandar di South Dakota
Teks kajian rasmi (Bahasa Inggeris)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Sanford USD Medical Center, Sioux Falls
Mengambil pesertaFasa 3
Umur 18 hingga 100 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Avera Cancer Institute, Sioux Falls
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06324357A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Avera McKennan Hospital ( Site 0002), Sioux Falls
- Avera Cancer Institute - Yankton ( Site 0089), Yankton
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06966700Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Sanford Health, Sioux Falls
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Sanford Cancer Center, Sioux Falls
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07174336A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Avera St. Mary's Hospital, Pierre
- Avera Cancer Institute, Sioux Falls
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT06492616A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
- Avera Cancer Institute - Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute - Pierre, SD, Pierre
- dan 2 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07405801A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Sioux Falls
Mengambil pesertaFasa 3
Umur 18 hingga 130 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07647328Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Avera Cancer Institute, Sioux Falls
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06982521Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Sanford - Sioux Falls, Sioux Falls
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 99 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT07211178Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Avera Cancer Institute-Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute at Pierre, Pierre
- dan 4 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 60 · Wanita · Dikemas kini 2 Sep 2026 · NCT05879926A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- Research Site, Aberdeen
- Research Site, Pierre
Mengambil pesertaFasa 3
Umur 18 hingga 130 · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT05774951E-Mindfulness Approaches for Living After Breast Cancer
- Rapid City Regional Hospital, Rapid City
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Mengambil pesertaFasa 3
Umur 18 hingga 50 · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT06748222A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Avera Cancer Institute, Sioux Falls
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT05377996Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Sanford Health, Sioux Falls
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Mei 2026 · NCT06757634I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Sanford Clinical Research, Sioux Falls
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mei 2026 · NCT01042379Avera Cancer Sequencing and Analytics Protocol (ASAP)
- Avera Cancer Institute - Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute - Pierre, Pierre
- dan 2 lagi
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Mac 2026 · NCT05142033Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Monument Health Rapid City Hospital, Rapid City
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06418204EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- Avera Cancer Institute, Sioux Falls
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Jan 2026 · NCT06401421Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.